IMMX Immix Biopharma, Inc.
Healthcare$8.78+1.27%ClosedMarket Cap: $477.7M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
3.98
P/S
0.00
EV/EBITDA
-11.22
DCF Value
$2.82
FCF Yield
-6.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.2%
ROA
-36.5%
ROIC
-42.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-10.8M | $-10.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-10.9M | $-10.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-27.2M | $-29.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.7M | $-7.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.7M | $-6.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-4.7M | $-4.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-5.0M | $-4.8M | $— | — |
| FY null | $0.00 | NaN% | $-22.7M | $-21.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.4M | $-7.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.7M | $-4.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-5.6M | $-5.3M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-5.4M | $-5.1M | $-0.26 | — |